Bristol-Myers Squibb : All NewsThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

ONGLYZA™ (Saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 DiabetesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PARIS & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that their marketing authorization application for ONGLYZA™ (saxagliptin) received a positive
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

ORENCIA® (abatacept) Demonstrates Consistent Safety and Effectiveness Over 7 YearsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
COPENHAGEN--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results of two ORENCIA® (abatacept) studies at the 2009 Annual European Congress of Rheumatology (EULAR) currently being held
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb Announces DividendEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-one cents ($0.31) per share on the $.10 par value Common Stock of the
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb to Present at Goldman Sachs Global Healthcare ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2009 in New York. Elliott Sigal, M.D., Ph.D., executive vice
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Interim Analysis of Long-Term Data with ONGLYZA™ (saxagliptin) When Added to Metformin in People with Inadequately Controlled Type 2 Diabetes Presented at ADA Annual Scientific SessionsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PRINCETON, N.J. & WILMINGTON, Del.--(BUSINESS WIRE)--Results from an interim analysis of a long-term Phase 3 study at 102 weeks with ONGLYZA™ (saxagliptin), an investigational, selective, reversible inhibitor of
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Dapagliflozin Study Demonstrated Improved Glycemic Control In Type 2 Diabetes Patients Treated With High Doses of Insulin and Common Oral Anti-Diabetic MedicinesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PRINCETON, N.J. & WILMINGTON, Del.--(BUSINESS WIRE)--Results from a 12-week study demonstrated that the investigational drug dapagliflozin, a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor,
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Exelixis and BMS Report Phase 2 Data to Be Presented at ASCO for XL184 in Patients with Previously Treated Glioblastoma MultiformeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported encouraging data from an ongoing phase 2 trial of XL184 in
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg/kg)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) today announced updated survival results from follow-up extensions of three Phase 2 ipilimumab studies of
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

First Phase III Data on Innovative Compound for Solid Organ Transplantation To be Featured at American Transplant CongressEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that belatacept, an investigational co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

FDA Grants Full Approval for SPRYCEL® (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec®*Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for SPRYCEL® (dasatinib) for the treatment of adults
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb to Present at Bernstein Strategic Decisions ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bernstein Strategic Decisions Conference on Wednesday, May 27, 2009 in New York. Jim Cornelius, chairman and chief executive
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Phase I Testing to Commence on Second Compound Developed from AMRI, Bristol-Myers Squibb CollaborationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (NASDAQ: AMRI) announced today that Bristol-Myers Squibb Company (NYSE: BMY) has submitted a Clinical Trial Application (CTA) to the Medical Products Agency (MPA) in Sweden for
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb Welcomes “Help is Here Express” to New BrunswickEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--With New Jersey’s unemployment rate hovering around 8.3 percent, thousands of residents are facing the loss of health insurance. Many, however, may be eligible for patient
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb to Present at Deutsche Bank Healthcare ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Deutsche Bank Healthcare Conference on Tuesday, May 19, 2009 in Boston. Jean-Marc Huet, executive vice president and chief
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

SPRYCEL® (Dasatinib) Shows Potential as Treatment for Prostate CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced interim results from two Phase II studies of SPRYCEL® (dasatinib) which demonstrate that the medicine may have potential as a
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb to Present at Bank of America and Merrill Lynch Health Care ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bank of America and Merrill Lynch Health Care Conference on Wednesday, May 13, 2009 in New York. Lamberto Andreotti, president and
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb to Present at Bernstein Pharmaceutical Emerging Markets ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will present at the Bernstein Pharmaceutical Emerging Markets Conference on Wednesday, May 6, 2009. John Celentano, president of Emerging Markets and
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb Invites Public to Listen to Webcast of 2009 Annual MeetingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) invites investors and the general public to listen to a webcast of its annual meeting with stockholders at 9:45 a.m. ET on Tuesday, May 5, 2009. In
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb Reports Excellent First Quarter Financial Results; Delivers on Two Significant Strategic InitiativesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced first quarter results which included excellent financial performance and successful execution of two key strategic initiatives. The
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb Announces Call for Entries for the 2009 REYATAZ® (atazanavir sulfate) “Fight HIV Your Way” ContestEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced the call for entries for the REYATAZ® (atazanavir sulfate) “Fight HIV Your Way” Contest for photographs with
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis CEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today reported that the administration of the investigational compound PEG-Interferon lambda in
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

U.S. Food and Drug Administration Extends Review Timeline for ONGLYZA™ (saxagliptin) New Drug ApplicationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) reported today that the U.S. Food and Drug Administration (FDA) has determined it needs additional time to
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb to Announce Results for the First Quarter of 2009 on April 28Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2009 on Tuesday, April 28. During an 11 a.m. (ET) conference call on April 28, company executives will
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY® and Establishment of an Oncology Collaboration with OtsukaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced an agreement with Otsuka Pharmaceutical Co., Ltd. (hereafter, “Otsuka”) to extend the U.S. portion of the
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

ONGLYZA™ (saxagliptin) Cardiovascular Profile Acceptable According to FDA Advisory CommitteeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Plavix(®) Plus Aspirin More Effective Than Aspirin Alone in Preventing Major Vascular Events in Patients with Atrial Fibrillation Who Cannot Take Oral AnticoagulantsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PARIS & PRINCETON, N.J.--(BUSINESS WIRE)--Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today new findings from a landmark investigational study that demonstrated
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Dapagliflozin Clinical Trial Results Indicate Improvement In Key Glycemic Measures In Treatment-Naïve Type 2 Diabetes PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Findings published today in Diabetes Care from a 12-week, Phase IIb dose-ranging study showed that dapagliflozin, a novel, selective, sodium glucose co-transporter2 (SGLT2)
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb to Present at Healthcare ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Cowen and Company 29th Annual Health Care Conference on Tuesday, March 17, 2009 in Boston. Brian Daniels, senior vice president,
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb to Present at Healthcare ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Barclay’s Capital Global Healthcare Conference on Tuesday, March 10, 2009 in Miami Beach, FL. Jean-Marc Huet, executive vice
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb Enters Global Collaboration with Nissan Chemical and Teijin Pharma on Novel Atrial Fibrillation CompoundEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced a global collaboration with Nissan Chemical Industries, Ltd. and Teijin Pharma Limited for the development and
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb Announces Organizational Changes; Names Four to Company’s Executive CommitteeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced a series of related organizational changes consistent with the company’s transformation to a next-generation BioPharma leader.
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb Names Andreotti President and Chief Operating OfficerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb Company (NYSE: BMY) today announced that Lamberto Andreotti, 58, has been elected president and chief operating officer, and a member of the company’s Board of
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX® in U.S.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY), and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the companies received a complete response
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb Foundation Announces Funding of More Than $1.17 Million to Bridge Gaps in Hepatitis C Awareness, Prevention and Care in China, India and TaiwanEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PRINCETON, N.J.--(BUSINESS WIRE)--The Bristol-Myers Squibb Foundation today announced funding of more than $1.17 million, focused on hepatitis C prevention and education and the mitigation of the disease in China,
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb Statement on Mead Johnson Nutrition Company IPOEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) issued the following statement on today’s initial public offering of Mead Johnson Nutrition Company (NYSE:MJN):
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Strong Fourth Quarter Supports Excellent 2008 for Bristol-Myers SquibbEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY):
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX®Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY), and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the companies have decided, after discussion
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb To Announce Results For The Fourth Quarter And Full Year Of 2008 On January 27Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter and full year of 2008 on Tuesday, January 27. During a 10:30 a.m. (ET) conference call on January 27,
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb to Present at Healthcare ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at a J.P. Morgan healthcare conference on Wednesday, January 14, 2009 in San Francisco. Elliott Sigal, M.D., Ph.D., executive vice
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb and ZymoGenetics Enter Global Collaboration on Novel Hepatitis C CompoundEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (Nasdaq: ZGEN) today announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Howard Feldman Joins Bristol-Myers Squibb as Vice President and Therapeutic Area Head, Global Clinical Research, NeuroscienceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that Dr. Howard Feldman has joined the company's Research and Development organization as vice president and therapeutic area
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Exelixis And Bristol-Myers Squibb Sign New Collaboration Agreement To Develop Novel Cardiovascular Disease Treatments Focus on LXR-Targeted Therapies for Atherosclerosis and Coronary Artery DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SOUTH SAN FRANCISCO, Calif. & NEW YORK--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a collaboration agreement to discover, develop and commercialize novel
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

New Data Demonstrate Significant Improvement in Progression-Free Survival for Triple Negative Metastatic Breast Cancer Patients Treated with IXEMPRA™ Plus CapecitabineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN ANTONIO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced new data from studies of IXEMPRA™ (ixabepilone) plus capecitabine compared to capectabine alone, including a pre-specified sub
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Sanofi-Aventis and Bristol-Myers Squibb Prevail before the U.S. Court of Appeals for the Federal Circuit in the U.S Plavix® Patent Infringement CaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PARIS & NEW YORK--(BUSINESS WIRE)--Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol-Myers Squibb (New York: NYSE: BMY) announced today that the U.S. Court of Appeals for the Federal
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

New Jersey Youth Get Rapid Access to Mental Health ServicesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PRINCETON, N.J.--(BUSINESS WIRE)--Children and adolescents from low-income households who need mental health care in New Jersey often face delays of weeks or even months for treatment. Now, a new program by a state
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer ProgramsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PRINCETON, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Exelixis, Inc. (Nasdaq: EXEL) today announced a global collaboration covering two novel molecules for cancer
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

Bristol-Myers Squibb to Announce 2003 Fourth Quarter and Full Year Earnings On January 29, 2004Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce 2003 fourth quarter and full year earnings on Thursday, January 29. During a conference call on that day at 10:30 a.m. (ET), financial
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations

ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug AdministrationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK--(BUSINESS WIRE)--ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY), and Bristol-Myers Squibb Company (NYSE: BMY) today announced that they have submitted an application to the
Source: Bristol-Myers Squibb : All News - July 5, 2009 Category: Pharmaceuticals Source Type: organizations